⌕
Acadia Pharmaceuticals · ACAD · Nasdaq
Tenet 65 · Solid
Compare
$18.32−1.87%At closeTenet 65 · Solid
$18.32−0.35 (−1.87%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Acadia Pharmaceuticals (ACAD) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ACAD's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 17, 2026 · 22:13 ET
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge

ACADIA Pharmaceuticals NASDAQ: ACAD is pursuing growth from its DAYBUE and NUPLAZID franchises while advancing neurological and psychiatric drug candidates and looking for external deals, CEO Catherine Owen Adams said at…

ACAD −1.9% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 12:52 ET
Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript

Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript…

ACAD −1.9% todayRead at source ↗
● Business WireNov 17, 2026 · 09:04 ETCOMPANY'S OWN WORDS
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated …

ACAD −1.9% todayRead at source ↗
● Business WireNov 16, 2026 · 09:04 ETCOMPANY'S OWN WORDS
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercializa…

ACAD −1.9% todayRead at source ↗
● Defense WorldNov 13, 2026 · 03:55 ET
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 35.1% during the third quarter, according to the company in its most recent filing with the Securities…

ACAD −1.9% todayRead at source ↗
● Business WireNov 9, 2026 · 23:47 ETCOMPANY'S OWN WORDS
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for th…

ACAD −1.9% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 01:34 ET
Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript

Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript…

ACAD −1.9% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 20:51 ET
Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.…

ACAD −1.9% todayRead at source ↗
● MarketBeatNov 4, 2026 · 20:15 ET
What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call

ACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson's disease psychosis…

ACAD −1.9% todayRead at source ↗
● Business WireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter, with total revenues …

ACAD −1.9% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD).  Such investors are advised to contact Danie…

ACAD −1.9% todayRead at source ↗
● Business WireOct 28, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m. G…

ACAD −1.9% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:06 ET
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

ACAD −1.9% todayRead at source ↗
● PRNewsWireOct 22, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Daniel…

ACAD −1.9% todayRead at source ↗
● Defense WorldOct 19, 2026 · 08:07 ET
Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports. They currently have a…

ACAD −1.9% todayRead at source ↗
● PRNewsWireOct 15, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Daniel…

ACAD −1.9% todayRead at source ↗
● Zacks Investment ResearchOct 13, 2026 · 11:06 ET
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.…

ACAD −1.9% todayRead at source ↗
● Defense WorldOct 12, 2026 · 02:15 ET
Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)

C4 Therapeutics (NASDAQ: CCCC - Get Free Report) and ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on …

ACAD −1.9% todayRead at source ↗
● Zacks Investment ResearchOct 9, 2026 · 11:31 ET
4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.…

ACAD −1.9% todayRead at source ↗
● PRNewsWireOct 8, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Daniell…

ACAD −1.9% todayRead at source ↗
● PRNewsWireOct 1, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD).  Such investors are advised to contact Daniel…

ACAD −1.9% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just ACAD · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.